Filter
Period
Filter by
recent search
Showing: 1 – 05 of 152 Regulated Information
–
11 July 2023
11 July 2023
IPSEN – Buy-back programme – Art 5 of MAR – Week 27 – 2023
Aggregated presentation by day and by market
–
10 July 2023
10 July 2023
–
10 July 2023
10 July 2023
Ipsen – Half year statement – 2023 06 30
Half-year statement of IPSEN liquidity agreement with NATIXIS ODDO BHF
–
04 July 2023
04 July 2023
IPSEN – Buy-back programme – Art 5 of MAR – Week 26 – 2023
Aggregated presentation by day and by market
–
30 June 2023
30 June 2023
Ipsen and GENFIT Announce Positive Results from Phase III ELATIVE trial of elafibranor in patients with primary biliary cholangitis, a rare cholestatic liver disease
PARIS, FRANCE, 30 June 2023 – Ipsen (Euronext: IPN; ADR: IPSEY) and GENFIT (Nasdaq and Euronext: GNFT) today announced positive topline data from the pivotal ELATIVE Phase III trial. In the trial the efficacy and safety of elafibranor, an investigational dual…